Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research

09-01-2025 | Diabetic Cardiomyopathy | Review

Long Non-Coding RNAs in Diabetic Cardiomyopathy: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training

Authors: Jie Hu, Xinwen Miao, Li-Hua Yu

Published in: Journal of Cardiovascular Translational Research

Login to get access

Abstract

Recent studies emphasize the beneficial effects of exercise on diabetic cardiomyopathy (DCM), adding to the growing body of evidence that underscores the role of exercise in improving health outcomes. Despite this, a notable gap persists in the number of healthcare providers who actively prescribe exercise as a therapeutic intervention for DCM management. In addition, exercise modulates the expression of lncRNAs, which play a pivotal role in DCM progression. Further investigation into this relationship may facilitate the identification of novel biomarkers and therapeutic targets for DCM. This review consolidates recent advances in identifying lncRNAs biomarkers in DCM, summarizing the current knowledge on dysregulated lncRNAs and their molecular mechanisms. Additionally, it offers new insights into the mechanistic roles of lncRNAs, highlighting their potential as biomarkers and therapeutic targets for DCM. Overall, this review aims to inform future research and reinforce the significance of addressing diabetes-related cardiovascular diseases to potentially improve clinical outcomes.

Graphical Abstract

Literature
1.
2.
Luo W, Lin K, Hua J, Han J, Zhang Q, Chen L, Khan ZA, Wu G, Wang Y, Liang G. Schisandrin B attenuates diabetic cardiomyopathy by Targeting MyD88 and inhibiting MyD88-dependent inflammation. Adv Sci (Weinh). 2022;9:e2202590.PubMedCrossRef
3.
Balakumar P, Maung-U K, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacol Res. 2016;113:600–9.PubMedCrossRef
4.
Hwang G-S, Yang J-Y, Ryu DH, Kwon T-H. Metabolic profiling of kidney and urine in rats with lithium-induced nephrogenic diabetes insipidus by (1)H-NMR-based metabonomics. Am J Physiol Renal Physiol. 2010;298:F461–70.PubMedCrossRef
5.
Sacramento JF, Chew DJ, Melo BF, Donegá M, Dopson W, Guarino MP, Robinson A, Prieto-Lloret J, Patel S, Holinski BJ, Ramnarain N, Pikov V, Famm K, Conde SV. Bioelectronic modulation of carotid sinus nerve activity in the rat: a potential therapeutic approach for type 2 diabetes. Diabetologia. 2018;61:700–10.PubMedPubMedCentralCrossRef
6.
Prasad R, Floyd JL, Dupont M, Harbour A, Adu-Agyeiwaah Y, Asare-Bediako B, Chakraborty D, Kichler K, Rohella A, Li Calzi S, Lammendella R, Wright J, Boulton ME, Oudit GY, Raizada MK, Stevens BR, Li Q, Grant MB. Maintenance of Enteral ACE2 Prevents Diabetic Retinopathy in Type 1 Diabetes. Circ Res. 2023;132(1):e1–21.PubMedCrossRef
7.
Tang Y, Zhang L, Ye D, Zhao A, Liu Y, Zhang M. Causal relationship between Type 1 diabetes and osteoporosis and fracture occurrence: a two-sample Mendelian randomization analysis. Osteoporos Int. 2023;34(6):1111–7.PubMedCrossRef
8.
Lavie CJ, Johannsen N, Swift D, Senechal M, Earnest C, Church T, Hutber A, Sallis R, Blair SN. Exercise is medicine - the importance of physical activity, exercise training, cardiorespiratory fitness and obesity in the prevention and treatment of type 2 diabetes. Eur Endocrinol. 2014;10:18–22.PubMedPubMedCentralCrossRef
9.
Jakicic JM, Jaramillo SA, Balasubramanyam A, Bancroft B, Curtis JM, Mathews A, Pereira M, Regensteiner JG, Ribisl PM, Look ASG. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the look AHEAD Study. Int J Obes (Lond). 2009;33:305–16.PubMedCrossRef
10.
Perry AS, Dooley EE, Master H, Spartano NL, Brittain EL, Pettee Gabriel K. Physical activity over the lifecourse and cardiovascular disease. Circ Res. 2023;132:1725–40.PubMedPubMedCentralCrossRef
11.
Dunstan DW, Salmon J, Healy GN, Shaw JE, Jolley D, Zimmet PZ, Owen N. Association of television viewing with fasting and 2-h postchallenge plasma glucose levels in adults without diagnosed diabetes. Diabetes Care. 2007;30:516–22.PubMedCrossRef
12.
Hemmingsen B, Gimenez-Perez G, Mauricio D, I Figuls MR, Metzendorf M-I, Richter B. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;12:CD003054.PubMed
13.
Petermann F, Díaz-Martínez X, Garrido-Méndez Á, Leiva AM, Martínez MA, Salas C, Poblete-Valderrama F, Celis-Morales C. Association between type 2 diabetes and physical activity in individuals with family history of diabetes. Gac Sanit. 2018;32:230–5.PubMedCrossRef
14.
Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW, Kubik M, Landefeld S, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng C-W, Wong JB. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US preventive services task force recommendation statement. JAMA. 2020;324:2069–75.PubMedCrossRef
15.
Balducci S, Sacchetti M, Haxhi J, Orlando G, D’Errico V, Fallucca S, Menini S, Pugliese G. Physical exercise as therapy for type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014;30(Suppl 1):13–23.PubMedCrossRef
16.
17.
Halabi N, Thomas B, Chidiac O, Robay A, AbiNahed J, Jayyousi A, Al Suwaidi J, Bradic M, Abi Khalil C. Dysregulation of long non-coding RNA gene expression pathways in monocytes of type 2 diabetes patients with cardiovascular disease. Cardiovasc Diabetol. 2024;23:196.PubMedPubMedCentralCrossRef
18.
Meng L, Lin H, Huang X, Weng J, Peng F, Wu S. METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA. Cell Death Dis. 2022;13:38.PubMedPubMedCentralCrossRef
19.
Dieter C, Lemos NE, Corrêa NRDF, Assmann TS, Crispim D. The impact of lncRNAs in diabetes mellitus: a systematic review and in silico analyses. Front Endocrinol (Lausanne). 2021;12:602597.PubMedPubMedCentralCrossRef
20.
Lu Y, Qie D, Yang F, Wu J. LncRNA MEG3 aggravates adipocyte inflammation and insulin resistance by targeting IGF2BP2 to activate TLR4/NF-κB signaling pathway. Int Immunopharmacol. 2023;121:110467.PubMedCrossRef
21.
Hu Z, Wang J, Pan T, Li X, Tao C, Wu Y, Wang X, Zhang Z, Liu Y, Zhang W, Xu C, Wu X, Gu Q, Fan Y, Qian H, Mugisha A, Yuan S, Liu Q, Xie P. The exosome-transmitted lncRNA LOC100132249 induces endothelial dysfunction in diabetic retinopathy. Diabetes. 2023;72:1307–19.PubMedCrossRef
22.
Chen K, Ou B, Huang Q, Deng D, Xiang Y, Hu F. LncRNA NEAT1 aggravates human microvascular endothelial cell injury by inhibiting the Apelin/Nrf2/HO-1 signalling pathway in type 2 diabetes mellitus with obstructive sleep apnoea. Epigenetics. 2024;19:2293409.PubMedPubMedCentralCrossRef
23.
Alharbi KS. GAS5: A pivotal lncRNA in diabetes mellitus pathogenesis and management. Pathol Res Pract. 2024;253:154955.PubMedCrossRef
24.
Xu Y, Kang X, Liu H, Jiang H, Wang W. LncRNA XIST promotes insulin resistance in gestational diabetes mellitus via the microRNA-181b-5p/NDRG2 axis. Gen Physiol Biophys. 2023;42:443–55.PubMedCrossRef
25.
Carter G, Miladinovic B, Patel AA, Deland L, Mastorides S, Patel NA. Circulating long noncoding RNA GAS5 levels are correlated to prevalence of type 2 diabetes mellitus. BBA Clin. 2015;4:102–7.PubMedPubMedCentralCrossRef
26.
Quaiyoom A, Kumar R. An overview of diabetic cardiomyopathy. Curr Diabetes Rev. 2024;20:e121023222139.PubMedCrossRef
27.
Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K, Matsuo N, Ichikawa K, Iwasaki K, Naito T, Namba Y, Yoshida M, Sugiyama H, Ito H. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int J Mol Sci. 2022;23(7):3587.PubMedPubMedCentralCrossRef
28.
29.
Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61:21–8.PubMedCrossRef
30.
Sung MM, Hamza SM, Dyck JR. Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets. Antioxid Redox Signal. 2015;22:1606–30.PubMedCrossRef
31.
Kyriazis ID, Hoffman M, Gaignebet L, Lucchese AM, Markopoulou E, Palioura D, Wang C, Bannister TD, Christofidou-Solomidou M, Oka SI, Sadoshima J, Koch WJ, Goldberg IJ, Yang VW, Bialkowska AB, Kararigas G, Drosatos K. KLF5 is induced by FOXO1 and causes oxidative stress and diabetic cardiomyopathy. Circ Res. 2021;128:335–57.PubMedCrossRef
32.
Dasari D, Goyal SG, Penmetsa A, Sriram D, Dhar A. Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function. Eur J Pharmacol. 2023;949:175720.PubMedCrossRef
33.
Zhang M, Sui W, Xing Y, Cheng J, Cheng C, Xue F, Zhang J, Wang X, Zhang C, Hao P, Zhang Y. Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis. Theranostics. 2021;11:8624–39.PubMedPubMedCentralCrossRef
34.
Shi X, Liu C, Chen J, Zhou S, Li Y, Zhao X, Xing J, Xue J, Liu F, Li F. Endothelial MICU1 alleviates diabetic cardiomyopathy by attenuating nitrative stress-mediated cardiac microvascular injury. Cardiovasc Diabetol. 2023;22:216.PubMedPubMedCentralCrossRef
35.
Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16:545–55.PubMedCrossRef
36.
Alkhatib A, Tsang C, Tiss A, Bahorun T, Arefanian H, Barake R, Khadir A, Tuomilehto J. Functional foods and lifestyle approaches for diabetes prevention and management. Nutrients. 2017;9(12):1310.PubMedPubMedCentralCrossRef
37.
Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–27.PubMedCrossRef
38.
Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ, Gross JL, Ribeiro JP, Schaan BD. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305:1790–9.PubMedCrossRef
39.
Jelleyman C, Yates T, O’Donovan G, Gray LJ, King JA, Khunti K, Davies MJ. The effects of high-intensity interval training on glucose regulation and insulin resistance: a meta-analysis. Obes Rev. 2015;16:942–61.PubMedCrossRef
40.
Rasmussen, L., Poulsen, C. W., Kampmann, U., Smedegaard, S. B., Ovesen, P. G. & Fuglsang, J. Diet and Healthy Lifestyle in the Management of Gestational Diabetes Mellitus, Nutrients. 2020;12.
41.
Joseph JJ, Echouffo-Tcheugui JB, Golden SH, Chen H, Jenny NS, Carnethon MR, Jacobs D, Burke GL, Vaidya D, Ouyang P, Bertoni AG. Physical activity, sedentary behaviors and the incidence of type 2 diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis (MESA). BMJ Open Diabetes Res Care. 2016;4:e000185.PubMedPubMedCentralCrossRef
42.
Smith AD, Crippa A, Woodcock J, Brage S. Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies. Diabetologia. 2016;59:2527–45.PubMedPubMedCentralCrossRef
43.
Moghetti P, Balducci S, Guidetti L, Mazzuca P, Rossi E, Schena F. Walking for subjects with type 2 diabetes: a systematic review and joint AMD/SID/SISMES evidence-based practical guideline. Nutr Metab Cardiovasc Dis. 2020;30:1882–98.PubMedCrossRef
44.
Pan B, Ge L, Xun Y-Q, Chen Y-J, Gao C-Y, Han X, Zuo L-Q, Shan H-Q, Yang K-H, Ding G-W, Tian J-H. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Int J Behav Nutr Phys Act. 2018;15:72.PubMedPubMedCentralCrossRef
45.
Sampath Kumar A, Maiya AG, Shastry BA, Vaishali K, Ravishankar N, Hazari A, Gundmi S, Jadhav R. Exercise and insulin resistance in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Phys Rehabil Med. 2019;62(2):98–103.PubMedCrossRef
46.
Tomas-Carus P, Ortega-Alonso A, Pietilainen KH, Santos V, Goncalves H, Ramos J, Raimundo A. A randomized controlled trial on the effects of combined aerobic-resistance exercise on muscle strength and fatigue, glycemic control and health-related quality of life of type 2 diabetes patients. J Sports Med Phys Fitness. 2016;56:572–8.PubMed
47.
Kriska A, Delahanty L, Edelstein S, Amodei N, Chadwick J, Copeland K, Galvin B, El Ghormli L, Haymond M, Kelsey M, Lassiter C, Mayer-Davis E, Milaszewski K, Syme A. Sedentary behavior and physical activity in youth with recent onset of type 2 diabetes. Pediatrics. 2013;131:e850–6.PubMedPubMedCentralCrossRef
48.
Brown RE, Riddell MC, Macpherson AK, Canning KL, Kuk JL. All-cause and cardiovascular mortality risk in U.S. adults with and without type 2 diabetes: influence of physical activity, pharmacological treatment and glycemic control. J Diabetes Complications. 2014;28:311–5.PubMedCrossRef
49.
Saunders TJ, McIsaac T, Douillette K, Gaulton N, Hunter S, Rhodes RE, Prince SA, Carson V, Chaput J-P, Chastin S, Giangregorio L, Janssen I, Katzmarzyk PT, Kho ME, Poitras VJ, Powell KE, Ross R, Ross-White A, Tremblay MS, Healy GN. Sedentary behaviour and health in adults: an overview of systematic reviews. Appl Physiol Nutr Metab. 2020;45:S197–217.PubMedCrossRef
50.
Poppe L, De Bourdeaudhuij I, Verloigne M, Shadid S, Van Cauwenberg J, Compernolle S, Crombez G. Efficacy of a self-regulation-based electronic and mobile health intervention targeting an active lifestyle in adults having type 2 diabetes and in adults aged 50 years or older: two randomized controlled trials. J Med Internet Res. 2019;21:e13363.PubMedPubMedCentralCrossRef
51.
Deng M-G, Cui H-T, Lan Y-B, Nie J-Q, Liang Y-H, Chai C. Physical activity, sedentary behavior, and the risk of type 2 diabetes: a two-sample Mendelian randomization analysis in the European population. Front Endocrinol (Lausanne). 2022;13:964132.PubMedCrossRef
52.
Bao W, Tobias DK, Bowers K, Chavarro J, Vaag A, Grunnet LG, Strøm M, Mills J, Liu A, Kiely M, Zhang C. Physical activity and sedentary behaviors associated with risk of progression from gestational diabetes mellitus to type 2 diabetes mellitus: a prospective cohort study. JAMA Intern Med. 2014;174:1047–55.PubMedPubMedCentralCrossRef
53.
Ghosh S, Paul M, Mondal KK, Bhattacharjee S, Bhattacharjee P. Sedentary lifestyle with increased risk of obesity in urban adult academic professionals: an epidemiological study in West Bengal, India. Sci Rep. 2023;13:4895.PubMedPubMedCentralCrossRef
54.
Lavie CJ, Ozemek C, Carbone S, Katzmarzyk PT, Blair SN. Sedentary behavior, exercise, and cardiovascular health. Circ Res. 2019;124:799–815.PubMedCrossRef
55.
Pant T, Dhanasekaran A, Fang J, Bai X, Bosnjak ZJ, Liang M, Ge ZD. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy. BMC Cardiovasc Disord. 2018;18:197.PubMedPubMedCentralCrossRef
56.
Schutte JP, Manke MC, Hemmen K, Munzer P, Schorg BF, Ramos GC, Pogoda M, Dicenta V, Hoffmann SHL, Pinnecker J, Kollotzek F, Zdanyte M, Mueller KAL, Singh Y, Mack AF, Pichler B, Lang F, Nieswandt B, Gawaz M, Heinze KG, Casadei N, Borst O. Platelet-derived microRNAs regulate cardiac remodeling after myocardial ischemia. Circ Res. 2023;132:e96–113.PubMedCrossRef
57.
Zhang Y, Zhao J, Jin Q, Zhuang L. Transcriptomic analyses and experimental validation identified immune-related lncRNA-mRNA pair MIR210HG-BPIFC regulating the progression of hypertrophic cardiomyopathy. Int J Mol Sci. 2024;25(5):2816.PubMedPubMedCentralCrossRef
58.
Baulina NM, Kiselev IS, Chumakova OS, Favorova OO. Circular RNAs: biogenesis, functions, and role in myocardial hypertrophy. Biochemistry (Mosc). 2024;89:S1–13.PubMedCrossRef
59.
Li H, Trager LE, Liu X, Hastings MH, Xiao C, Guerra J, To S, Li G, Yeri A, Rodosthenous R, Silverman MG, Das S, Ambardekar AV, Bristow MR, González-Rosa JM, Rosenzweig A. lncExACT1 and DCHS2 regulate physiological and pathological cardiac growth. Circulation. 2022;145:1218–33.PubMedPubMedCentralCrossRef
60.
Lin H, Zhu Y, Zheng C, Hu D, Ma S, Chen L, Wang Q, Chen Z, Xie J, Yan Y, Huang X, Liao W, Kitakaze M, Bin J, Liao Y. Antihypertrophic memory after regression of exercise-induced physiological myocardial hypertrophy is mediated by the long noncoding RNA Mhrt779. Circulation. 2021;143:2277–92.PubMedPubMedCentralCrossRef
61.
Gao R, Wang L, Bei Y, Wu X, Wang J, Zhou Q, Tao L, Das S, Li X, Xiao J. Long noncoding RNA cardiac physiological hypertrophy-associated regulator induces cardiac physiological hypertrophy and promotes functional recovery after myocardial ischemia-reperfusion injury. Circulation. 2021;144:303–17.PubMedCrossRef
62.
Chen Y, Tan S, Liu M, Li J. LncRNA TINCR is downregulated in diabetic cardiomyopathy and relates to cardiomyocyte apoptosis. Scand Cardiovasc J. 2018;52:335–9.PubMedCrossRef
63.
Yang F, Qin Y, Wang Y, Li A, Lv J, Sun X, Che H, Han T, Meng S, Bai Y, Wang L. LncRNA KCNQ1OT1 mediates pyroptosis in diabetic cardiomyopathy. Cell Physiol Biochem. 2018;50:1230–44.PubMedCrossRef
64.
Li Q, Li P, Su J, Liu S, Yang X, Yang Y, Niu S. LncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values. Exp Ther Med. 2019;18:1221–5.PubMedPubMedCentral
65.
Ren S, Zhang Y, Li B, Bu K, Wu L, Lu Y, Lu Y, Qiu Y. Downregulation of lncRNA-SRA participates in the development of cardiovascular disease in type II diabetic patients. Exp Ther Med. 2019;17:3367–72.PubMedPubMedCentral
66.
Jia P, Wu N, Jia D, Sun Y. Downregulation of MALAT1 alleviates saturated fatty acid-induced myocardial inflammatory injury via the miR-26a/HMGB1/TLR4/NF-kappaB axis. Diabetes Metab Syndr Obes. 2019;12:655–65.PubMedPubMedCentralCrossRef
67.
Qi K, Zhong J. LncRNA HOTAIR improves diabetic cardiomyopathy by increasing viability of cardiomyocytes through activation of the PI3K/Akt pathway. Exp Ther Med. 2018;16:4817–23.PubMedPubMedCentral
68.
Gao L, Wang X, Guo S, Xiao L, Liang C, Wang Z, Li Y, Liu Y, Yao R, Liu Y, Zhang Y. LncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR-34a in diabetic cardiomyopathy. J Cell Physiol. 2019;234:4944–58.PubMedCrossRef
69.
Yu W, Zhao G-Q, Cao R-J, Zhu Z-H, Li K. LncRNA NONRATT021972 was associated with neuropathic pain scoring in patients with type 2 diabetes. Behav Neurol. 2017;2017:2941297.PubMedPubMedCentralCrossRef
70.
Xu H, Liu C, Rao S, He L, Zhang T, Sun S, Wu B, Zou L, Wang S, Xue Y, Jia T, Zhao S, Li G, Liu S, Li G, Liang S. LncRNA NONRATT021972 siRNA rescued decreased heart rate variability in diabetic rats in superior cervical ganglia. Auton Neurosci. 2016;201:1–7.PubMedCrossRef
71.
Zhao SF, Ye YX, Xu JD, He Y, Zhang DW, Xia ZY, Wang S. Long non-coding RNA KCNQ1OT1 increases the expression of PDCD4 by targeting miR-181a-5p, contributing to cardiomyocyte apoptosis in diabetic cardiomyopathy. Acta Diabetol. 2021;58:1251–67.PubMedCrossRef
72.
Yang F, Qin Y, Lv J, Wang Y, Che H, Chen X, Jiang Y, Li A, Sun X, Yue E, Ren L, Li Y, Bai Y, Wang L. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy. Cell Death Dis. 2018;9:1000.PubMedPubMedCentralCrossRef
73.
Tang H, Zhong H, Liu W, Wang Y, Wang Y, Wang L, Tang S, Zhu H. Melatonin alleviates hyperglycemia-induced cardiomyocyte apoptosis via regulation of long non-coding RNA H19/miR-29c/MAPK axis in diabetic cardiomyopathy. Pharmaceuticals (Basel). 2022;15(7):821.PubMedCrossRef
74.
Zhuo C, Jiang R, Lin X, Shao M. LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Oncotarget. 2017;8:1429–37.PubMedCrossRef
75.
Wang S, Duan J, Liao J, Wang Y, Xiao X, Li L, Liu Y, Gu H, Yang P, Fu D, Du J, Li X, Shao M. LncRNA H19 inhibits ER stress induced apoptosis and improves diabetic cardiomyopathy by regulating PI3K/AKT/mTOR axis. Aging (Albany NY). 2022;14:6809–28.PubMedCrossRef
76.
Xue Y, Zhang J, Ke J, Zeng L, Cheng K, Han X, Chen F, Chen F. LncGBP9 knockdown alleviates myocardial inflammation and apoptosis in mice with acute viral myocarditis via suppressing NF-kappaB signaling pathway. Inflamm Res. 2022;71:1559–76.PubMedCrossRef
77.
Wu H, Liu J, Li W, Liu G, Li Z. LncRNA-HOTAIR promotes TNF-alpha production in cardiomyocytes of LPS-induced sepsis mice by activating NF-kappaB pathway. Biochem Biophys Res Commun. 2016;471:240–6.PubMedCrossRef
78.
Ji L, Han H, Shan X, Zhao P, Chen H, Zhang C, Xu M, Lu R, Guo W. Ginsenoside Rb1 ameliorates lipotoxicity-induced myocardial injury in diabetes mellitus by regulating Mfn2. Eur J Pharmacol. 2024;974:176609.PubMedCrossRef
79.
Yue Q, Zhao C, Wang Y, Zhao L, Zhu Q, Li G, Wu N, Jia D, Ma C. Downregulation of growth arrest-specific transcript 5 alleviates palmitic acid-induced myocardial inflammatory injury through the miR-26a/HMGB1/NF-kappaB axis. Mol Med Rep. 2018;18:5742–50.PubMed
80.
Li Y, Song B, Liu J, Li Y, Wang J, Liu N, Cui W. The interplay between HIF-1alpha and long noncoding GAS5 regulates the JAK1/STAT3 signalling pathway in hypoxia-induced injury in myocardial cells. Cardiovasc Diagn Ther. 2021;11:422–34.PubMedPubMedCentralCrossRef
81.
Zhang L, Wang YM. Expression and function of lncRNA ANRIL in a mouse model of acute myocardial infarction combined with type 2 diabetes mellitus. J Chin Med Assoc. 2019;82:685–92.PubMedCrossRef
82.
Dai W, Lee D. Interfering with long chain noncoding RNA ANRIL expression reduces heart failure in rats with diabetes by inhibiting myocardial oxidative stress. J Cell Biochem. 2019;120:18446–56.PubMedCrossRef
83.
84.
Ma X, Mei S, Wuyun Q, Zhou L, Cai Z, Ding H, Yan J. Super-enhancer-driven LncRNA PPARalpha-seRNA exacerbates glucolipid metabolism and diabetic cardiomyopathy via recruiting KDM4B. Mol Metab. 2024;86:101978.PubMedPubMedCentralCrossRef
85.
Luo Y, Jiang Y, Zhong T, Li Z, He J, Li X, Cui K. LncRNA HCG18 affects diabetic cardiomyopathy and its association with miR-9-5p/IGF2R axis. Heliyon. 2024;10:e24604.PubMedPubMedCentralCrossRef
86.
Xie R, Fan J, Wen J, Jin K, Zhan J, Yuan S, Tang Y, Nie X, Wen Z, Li H, Chen C, Wang DW. LncRNA ZNF593-AS alleviates diabetic cardiomyopathy via suppressing IRF3 signaling pathway. Mol Ther Nucleic Acids. 2023;32:689–703.PubMedPubMedCentralCrossRef
87.
Riddell MC, Gallen IW, Smart CE, Taplin CE, Adolfsson P, Lumb AN, Kowalski A, Rabasa-Lhoret R, McCrimmon RJ, Hume C, Annan F, Fournier PA, Graham C, Bode B, Galassetti P, Jones TW, Millán IS, Heise T, Peters AL, Petz A, Laffel LM. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017;5:377–90.PubMedCrossRef
88.
Riddell MC, Peters AL. Exercise in adults with type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19(2):98–111.PubMedCrossRef
89.
Zheng J, Cheng J, Zheng S, Zhang L, Guo X, Zhang J, Xiao X. Physical exercise and its protective effects on diabetic cardiomyopathy: what is the evidence? Front Endocrinol (Lausanne). 2018;9:729.PubMedCrossRef
90.
Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19:143–57.PubMedCrossRef
91.
Yang Q, Chen S, Wang X, Yang X, Chen L, Huang T, Zheng Y, Zheng X, Wu X, Sun Y, Wu J. Exercise mitigates endothelial pyroptosis and atherosclerosis by downregulating NEAT1 through N6-methyladenosine modifications. Arterioscler Thromb Vasc Biol. 2023;43:910–26.PubMedCrossRef
92.
Wu B, Xu C, Tian Y, Zeng Y, Yan F, Chen A, Zhao J, Chen L. Aerobic exercise promotes the expression of ATGL and attenuates inflammation to improve hepatic steatosis via lncRNA SRA. Sci Rep. 2022;12:5370.PubMedPubMedCentralCrossRef
93.
Yue Y, Yue Y, Fan Z, Meng Y, Wen C, An Y, Yao Y, Li X. The long noncoding RNA lnc-H19 is important for endurance exercise by maintaining slow muscle fiber types. J Biol Chem. 2023;299:105281.PubMedPubMedCentralCrossRef
94.
Yang Q, Fang D, Chen J, Hu S, Chen N, Jiang J, Zeng M, Luo M. LncRNAs associated with oxidative stress in diabetic wound healing: regulatory mechanisms and application prospects. Theranostics. 2023;13:3655–74.PubMedPubMedCentralCrossRef
95.
Wang K, Lin Y, Shen H, Yu S, Xu J. LncRNA TUG1 Exacerbates myocardial fibrosis in diabetic cardiomyopathy by modulating the microRNA-145a-5p/Cfl2 Axis. J Cardiovasc Pharmacol. 2023;81:192–202.PubMedCrossRef
96.
Zhu C, Zhang H, Wei D, Sun Z. Silencing lncRNA GAS5 alleviates apoptosis and fibrosis in diabetic cardiomyopathy by targeting miR-26a/b-5p. Acta Diabetol. 2021;58:1491–501.PubMedCrossRef
97.
Feng Y, Xu W, Zhang W, Wang W, Liu T, Zhou X. LncRNA DCRF regulates cardiomyocyte autophagy by targeting miR-551b-5p in diabetic cardiomyopathy. Theranostics. 2019;9:4558–66.PubMedPubMedCentralCrossRef
98.
Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, Tao ZF, Song YC, Chen Q, Jiang Q. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015;116:1143–56.PubMedCrossRef
99.
Shi C, Wu L, Li L. LncRNA-MALAT 1 regulates cardiomyocyte scorching in diabetic cardiomyopathy by targeting NLRP3. Cell Mol Biol (Noisy-le-grand). 2022;67:213–9.PubMedCrossRef
100.
Liu L, An X, Li Z, Song Y, Li L, Zuo S, Liu N, Yang G, Wang H, Cheng X, Zhang Y, Yang X, Wang J. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Cardiovasc Res. 2016;111:56–65.PubMedCrossRef
101.
Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S, Thum T. Long noncoding RNA chast promotes cardiac remodeling. Sci Transl Med. 2016;8:326ra22.PubMedCrossRef
102.
Qian Y, Zhang M, Zhou N, Xu X, Zhang J, Ding Q, Wang J. A long noncoding RNA CHAIR protects the heart from pathological stress. Clin Sci (Lond). 2020;134:1843–57.PubMedCrossRef
103.
Viereck J, Buhrke A, Foinquinos A, Chatterjee S, Kleeberger JA, Xiao K, Janssen-Peters H, Batkai S, Ramanujam D, Kraft T, Cebotari S, Gueler F, Beyer AM, Schmitz J, Brasen JH, Schmitto JD, Gyongyosi M, Loser A, Hirt MN, Eschenhagen T, Engelhardt S, Bar C, Thum T. Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. Eur Heart J. 2020;41:3462–74.PubMedPubMedCentralCrossRef
104.
105.
Wang S, Li J, Zhao Y. Construction and analysis of a network of exercise-induced mitochondria-related non-coding RNA in the regulation of diabetic cardiomyopathy. PLoS One. 2024;19:e0297848.PubMedPubMedCentralCrossRef
106.
Lin X, Qu J, Yin L, Wang R, Wang X. Aerobic exercise-induced decrease of chemerin improved glucose and lipid metabolism and fatty liver of diabetes mice through key metabolism enzymes and proteins. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868:159409.PubMedCrossRef
107.
Liu S-X, Zheng F, Xie K-L, Xie M-R, Jiang L-J, Cai Y. Exercise reduces insulin resistance in type 2 diabetes mellitus via mediating the lncRNA MALAT1/MicroRNA-382-3p/Resistin axis. Mol Ther Nucleic Acids. 2019;18:34–44.PubMedPubMedCentralCrossRef
108.
Wang M, Xie K, Zhao S, Jia N, Zong Y, Gu W, Cai Y. Aerobic exercise improves cognitive impairment in mice with type 2 diabetes by regulating the MALAT1/miR-382-3p/BDNF signaling pathway in serum-exosomes. Mol Med. 2023;29:130.PubMedPubMedCentralCrossRef
109.
An T, He Z-C, Zhang X-Q, Li J, Chen A-L, Tan F, Chen H-D, Lv B-H, Lian J, Gao S-H, Jiang G-J. Baduanjin exerts anti-diabetic and anti-depression effects by regulating the expression of mRNA, lncRNA, and circRNA. Chin Med. 2019;14:3.PubMedPubMedCentralCrossRef
110.
Sylow L, Kleinert M, Richter EA, Jensen TE. Exercise-stimulated glucose uptake - regulation and implications for glycaemic control. Nat Rev Endocrinol. 2017;13:133–48.PubMedCrossRef
111.
Hawley JA, Lessard SJ. Exercise training-induced improvements in insulin action. Acta Physiol (Oxf). 2008;192:127–35.PubMedCrossRef
112.
Trewin AJ, Silver J, Dillon HT, Della Gatta PA, Parker L, Hiam DS, Lee YP, Richardson M, Wadley GD, Lamon S. Long non-coding RNA Tug1 modulates mitochondrial and myogenic responses to exercise in skeletal muscle. BMC Biol. 2022;20:164.PubMedPubMedCentralCrossRef
113.
Costa-Júnior JM, Ferreira SM, Kurauti MA, Bernstein DL, Ruano EG, Kameswaran V, Schug J, Freitas-Dias R, Zoppi CC, Boschero AC, Oliveira CAMD, Santos GJ, Carneiro EM, Kaestner KH. Paternal exercise improves the metabolic health of offspring via epigenetic modulation of the germline. Int J Mol Sci. 2021;23(1):1.PubMedPubMedCentralCrossRef
114.
Durr AJ, Hathaway QA, Kunovac A, Taylor AD, Pinti MV, Rizwan S, Shepherd DL, Cook CC, Fink GK, Hollander JM. Manipulation of the miR-378a/mt-ATP6 regulatory axis rescues ATP synthase in the diabetic heart and offers a novel role for lncRNA Kcnq1ot1. Am J Physiol Cell Physiol. 2022;322:C482–95.PubMedPubMedCentralCrossRef
115.
Zhang Q, Li D, Dong X, Zhang X, Liu J, Peng L, Meng B, Hua Q, Pei X, Zhao L, Hu X, Zhang Y, Pan Z, Lu Y, Yang B. LncDACH1 promotes mitochondrial oxidative stress of cardiomyocytes by interacting with sirtuin3 and aggravates diabetic cardiomyopathy. Sci China Life Sci. 2022;65:1198–212.PubMedCrossRef
116.
Xiao W, Zheng D, Chen X, Yu B, Deng K, Ma J, Wen X, Hu Y, Hou J. Long non-coding RNA MIAT is involved in the regulation of pyroptosis in diabetic cardiomyopathy via targeting miR-214–3p. iScience. 2021;24:103518.PubMedPubMedCentralCrossRef
117.
Liu Y, Zhu Y, Liu S, Liu J, Li X. NORAD lentivirus shRNA mitigates fibrosis and inflammatory responses in diabetic cardiomyopathy via the ceRNA network of NORAD/miR-125a-3p/Fyn. Inflamm Res. 2021;70:1113–27.PubMedCrossRef
118.
Xu Y, Fang H, Xu Q, Xu C, Yang L, Huang C. LncRNA GAS5 inhibits NLRP3 inflammasome activation-mediated pyroptosis in diabetic cardiomyopathy by targeting miR-34b-3p/AHR. Cell Cycle. 2020;19:3054–65.PubMedPubMedCentralCrossRef
119.
Abo-Saif MA, Ragab AE, Ibrahim AO, Abdelzaher OF, Mehanyd ABM, Saber-Ayad M, El-Feky OA. Pomegranate peel extract protects against the development of diabetic cardiomyopathy in rats by inhibiting pyroptosis and downregulating LncRNA-MALAT1. Front Pharmacol. 2023;14:1166653.PubMedPubMedCentralCrossRef
120.
Li X, Wang H, Yao B, Xu W, Chen J, Zhou X. lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Sci Rep. 2016;6:36340.PubMedPubMedCentralCrossRef
121.
Sun H, Wang C, Zhou Y, Cheng X. Long noncoding RNA OIP5-AS1 overexpression promotes viability and inhibits high glucose-induced oxidative stress of cardiomyocytes by targeting microRNA-34a/SIRT1 axis in diabetic cardiomyopathy. Endocr Metab Immune Disord Drug Targets. 2021;21:2017–27.PubMedCrossRef
122.
Hu L, Xu Y-N, Wang Q, Liu M-J, Zhang P, Zhao L-T, Liu F, Zhao D-Y, Pei H-N, Yao X-B, Hu H-G. Aerobic exercise improves cardiac function in rats with chronic heart failure through inhibition of the long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). Ann Transl Med. 2021;9:340.PubMedPubMedCentralCrossRef
123.
Farsangi SJ, Rostamzadeh F, Sheikholeslami M, Jafari E, Karimzadeh M. Modulation of the expression of long non-coding RNAs H19, GAS5, and MIAT by endurance exercise in the hearts of rats with myocardial infarction. Cardiovasc Toxicol. 2021;21:162–8.PubMedCrossRef
124.
He Y, Qiang Y. Mechanism of autonomic exercise improving cognitive function of Alzheimer’s disease by regulating lncRNA SNHG14. Am J Alzheimers Dis Other Demen. 2021;36:15333175211027680.PubMedPubMedCentralCrossRef
125.
Chen W, Ye Q, Dong Y. Long term exercise-derived exosomal LncRNA CRNDE mitigates myocardial infarction injury through miR-489-3p/Nrf2 signaling axis. Nanomedicine. 2023;55:102717.PubMedCrossRef
126.
Lu J, Liu L, Chen J, Zhi J, Li J, Li L, Jiang Z. LncRNA HOTAIR in exercise-induced neuro-protective function in Alzheimer’s disease. Folia Neuropathol. 2022;60:414–20.PubMedCrossRef
127.
Lu J, Liu L, Chen J, Zhi J, Li J, Li L, Jiang Z. The involvement of lncRNA HOTAIR/miR-130a-3p axis in the regulation of voluntary exercise on cognition and inflammation of Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2022;37:15333175221091424.PubMedPubMedCentralCrossRef
128.
Wu B, Ding J, Chen A, Song Y, Xu C, Tian F, Zhao J. Aerobic exercise improves adipogenesis in diet-induced obese mice via the lncSRA/p38/JNK/PPARgamma pathway. Nutr Res. 2022;105:20–32.PubMedCrossRef
129.
Mayega RW, Guwatudde D, Makumbi FE, Nakwagala FN, Peterson S, Tomson G, Ostenson C-G. Comparison of fasting plasma glucose and haemoglobin A1c point-of-care tests in screening for diabetes and abnormal glucose regulation in a rural low income setting. Diabetes Res Clin Pract. 2014;104:112–20.PubMedCrossRef
130.
Liu S, Jiao B, Zhao H, Liang X, Jin F, Liu X, Hu J-F. LncRNAs-circRNAs as rising epigenetic binary superstars in regulating lipid metabolic reprogramming of cancers. Adv Sci (Weinh). 2024;11:e2303570.PubMedCrossRef
131.
Coan M, Haefliger S, Ounzain S, Johnson R. Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Genet. 2024;25(8):578–95.PubMedCrossRef
132.
Li T, Hu D, Gong Y. Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing. J Matern Fetal Neona. 2022;35:5125–39.CrossRef
133.
Li X, Zhu J, Zhong Y, Liu C, Yao M, Sun Y, Yao W, Ni X, Zhou F, Yao J, Jiang Q. Targeting long noncoding RNA-AQP4-AS1 for the treatment of retinal neurovascular dysfunction in diabetes mellitus. EBioMedicine. 2022;77:103857.PubMedPubMedCentralCrossRef
134.
Alrefai AA, Khader HF, Elbasuony HA, Elzorkany KM, Saleh AA. Evaluation of the expression levels of lncRNAs H19 and MEG3 in patients with type 2 diabetes mellitus. Mol Biol Rep. 2023;50:6075–85.PubMedCrossRef
135.
Jiang W, Sun X, Liu F, Cheng G, Li S, Xu M, Wu Y, Wang L. Circulating lncRNAs NONHSAT054669.2 and ENST00000525337 can be used as early biomarkers of gestational diabetes mellitus. Exp Biol Med (Maywood). 2023;248:508–18.PubMedCrossRef
136.
Huang X, Wu W, Jing D, Yang L, Guo H, Wang L, Zhang W, Pu F, Shao Z. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy. J Control Release. 2022;343:107–17.PubMedCrossRef
137.
Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, Ke X, Wu J, Yuan J. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17:2606–21.PubMedPubMedCentralCrossRef
138.
Li Y, Lou S, Zhang J, Zhao S, Lou G. m6A methylation-mediated regulation of LncRNA MEG3 suppresses ovarian cancer progression through miR-885-5p and the VASH1 pathway. J Transl Med. 2024;22:113.PubMedPubMedCentralCrossRef
139.
Hope C, Robertshaw A, Cheung KL, Idris I, English E. Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabet Med. 2016;33:1013–25.PubMedCrossRef
140.
Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2015;30:529–42.PubMedCrossRef
141.
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491–7.PubMedCrossRef
142.
Mosaad H, Shalaby SM, Mahmoud NM, Ahmed MM, Fayed A, Ashour HR, Sarhan W. LncRNA ANRIL promotes glucose metabolism and proliferation of colon cancer in a high-glucose environment and is associated with worse outcome in diabetic colon cancer patients. Asian Pac J Cancer Prev. 2024;25:1371–81.PubMedPubMedCentralCrossRef
143.
Kang H, Ga YJ, Kim SH, Cho YH, Kim JW, Kim C, Yeh JY. Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges. J Biomed Sci. 2023;30:88.PubMedPubMedCentralCrossRef
144.
Jiang M, Song Y, Ren MX, He RC, Dong XH, Li XH, Lu ZF, Li S, Wu J, Bei YR, Liu F, Long Y, Wu SG, Liu XH, Wu LM, Yang HL, McVey DG, Dai XY, Ye S, Hu YW. LncRNA NIPA1-SO confers atherosclerotic protection by suppressing the transmembrane protein NIPA1. J Adv Res. 2023;54:29–42.PubMedPubMedCentralCrossRef
145.
Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gulla A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018;132:1050–63.PubMedPubMedCentralCrossRef
146.
147.
Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018;32:1948–57.PubMedPubMedCentralCrossRef
148.
Shaath H, Vishnubalaji R, Elango R, Kardousha A, Islam Z, Qureshi R, Alam T, Kolatkar PR, Alajez NM. Long non-coding RNA and RNA-binding protein interactions in cancer: experimental and machine learning approaches. Semin Cancer Biol. 2022;86:325–45.PubMedCrossRef
149.
Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108–19.PubMedPubMedCentralCrossRef
150.
Yang H, Jiang Y, Zhang Y, Xu Y, Zhang C, Han J, Su F, Liu X, Mi K, Liu B, Shang D. System level characterization of small molecule drugs and their affected long noncoding RNAs. Aging (Albany NY). 2019;11:12428–51.PubMedCrossRef
151.
Pedram Fatemi R, Salah-Uddin S, Modarresi F, Khoury N, Wahlestedt C, Faghihi MA. Screening for small-molecule modulators of long noncoding RNA-protein interactions using AlphaScreen. J Biomol Screen. 2015;20:1132–41.PubMedPubMedCentralCrossRef
152.
Chen L, Zheng X, Liu W, Sun Y, Zhao S, Tian L, Tian W, Xue F, Kang C, Wang Y. Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer. Cancer Lett. 2023;578:216445.PubMedCrossRef
153.
Yang E, Hong B, Wang Y, Wang Q, Zhao J, Cui X, Wu Y, Yang S, Su D, Liu X, Kang C. EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma. Cancer Lett. 2024;588:216812.PubMedCrossRef
154.
Li C-H, Xiao Z, Tong JH-M, To K-F, Fang X, Cheng AS, Chen Y. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma. Int J Cancer. 2017;140:120–9.PubMedCrossRef
155.
Fiuza-Luces C, Santos-Lozano A, Joyner M, Carrera-Bastos P, Picazo O, Zugaza JL, Izquierdo M, Ruilope LM, Lucia A. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat Rev Cardiol. 2018;15:731–43.PubMedCrossRef
156.
Schroeder EC, Franke WD, Sharp RL, Lee DC. Comparative effectiveness of aerobic, resistance, and combined training on cardiovascular disease risk factors: a randomized controlled trial. PLoS One. 2019;14:e0210292.PubMedPubMedCentralCrossRef
157.
Marzolini S, Oh PI, Brooks D. Effect of combined aerobic and resistance training versus aerobic training alone in individuals with coronary artery disease: a meta-analysis. Eur J Prev Cardiol. 2012;19:81–94.PubMedCrossRef
158.
159.
Chen H, Chen C, Spanos M, Li G, Lu R, Bei Y, Xiao J. Exercise training maintains cardiovascular health: signaling pathways involved and potential therapeutics. Signal Transduct Target Ther. 2022;7:306.PubMedPubMedCentralCrossRef
160.
Jin L, Geng L, Ying L, Shu L, Ye K, Yang R, Liu Y, Wang Y, Cai Y, Jiang X, Wang Q, Yan X, Liao B, Liu J, Duan F, Sweeney G, Woo CWH, Wang Y, Xia Z, Lian Q, Xu A. FGF21-Sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity. Circulation. 2022;146:1537–57.PubMedCrossRef
161.
Moraes-Silva IC, Rodrigues B, Coelho-Junior HJ, Feriani DJ, Irigoyen MC. Myocardial infarction and exercise training: evidence from basic science. Adv Exp Med Biol. 2017;999:139–53.PubMedCrossRef
162.
Sacre JW, Jellis CL, Jenkins C, Haluska BA, Baumert M, Coombes JS, Marwick TH. A six-month exercise intervention in subclinical diabetic heart disease: effects on exercise capacity, autonomic and myocardial function. Metabolism. 2014;63:1104–14.PubMedCrossRef
163.
Wisloff U, Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram PM, Tjonna AE, Helgerud J, Slordahl SA, Lee SJ, Videm V, Bye A, Smith GL, Najjar SM, Ellingsen O, Skjaerpe T. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation. 2007;115:3086–94.PubMedCrossRef
164.
Mably JD, Wang D-Z. Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects. Nat Rev Cardiol. 2024;21:326–45.PubMedCrossRef
165.
Huang S-F, Zhao G, Peng X-F, Ye W-C. The pathogenic role of long non-coding RNA H19 in atherosclerosis via the miR-146a-5p/ANGPTL4 pathway. Front Cardiovasc Med. 2021;8:770163.PubMedPubMedCentralCrossRef
166.
Liu Z-Z, Lin W-J, Feng Y, Huang C-L, Yan Y-F, Guo W-Y, Zhang H, Lei Z, Lu Q-L, Liu P, Lin X-M, Wu S-D. Plasma lncRNA LIPCAR expression levels associated with neurological impairment and stroke subtypes in patients with acute cerebral infarction: a prospective observational study with a control group. Neurol Ther. 2023;12:1385–98.PubMedPubMedCentralCrossRef
167.
Leisegang MS, Warwick T, Stötzel J, Brandes RP. RNA-DNA triplexes: molecular mechanisms and functional relevance. Trends Biochem Sci. 2024;49:532–44.PubMedCrossRef
168.
Matboli M, Kamel MM, Essawy N, Bekhit MM, Abdulrahman B, Mohamed GF, Eissa S. Identification of novel insulin resistance related ceRNA network in T2DM and its potential editing by CRISPR/Cas9. Int J Mol Sci. 2021;22(15):8129.PubMedPubMedCentralCrossRef
169.
Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96–118.PubMedCrossRef
170.
Davodabadi F, Mirinejad S, Malik S, Dhasmana A, Ulucan-Karnak F, Sargazi S, Sargazi S, Fathi-Karkan S, Rahdar A. Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer. Nanoscale. 2024;16:3881–914.PubMedCrossRef
171.
Chen J, Jamaiyar A, Wu W, Hu Y, Zhuang R, Sausen G, Cheng HS, de Oliveira Vaz C, Pérez-Cremades D, Tzani A, McCoy MG, Assa C, Eley S, Randhawa V, Lee K, Plutzky J, Hamburg NM, Sabatine MS, Feinberg MW. Deficiency of lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis. Cell Rep. 2024;43:113815.PubMedPubMedCentralCrossRef
172.
Su X, Huang H, Lai J, Lin S, Huang Y. Long noncoding RNAs as potential diagnostic biomarkers for diabetes mellitus and complications: a systematic review and meta-analysis. J Diabetes. 2023;16(2):e13510.PubMedPubMedCentralCrossRef
Metadata
Title
Long Non-Coding RNAs in Diabetic Cardiomyopathy: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training
Authors
Jie Hu
Xinwen Miao
Li-Hua Yu
Publication date
09-01-2025
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-024-10586-8

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now
Image Credits